» Articles » PMID: 21545189

Do Productivity Costs Matter?: the Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders

Overview
Specialty Pharmacology
Date 2011 May 7
PMID 21545189
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the results of cost-effectiveness studies, particularly those regarding treatments targeted at diseases with a high incidence rate in the working population, such as depressive disorders.

Objectives: This study aimed to, first, investigate whether economic evaluations of treatments for depressive disorders include productivity costs and, if so, how. Second, to investigate how the inclusion or exclusion of productivity costs affects incremental costs.

Methods: A systematic literature review was performed. Included articles were reviewed to determine (i) whether productivity costs had been included and (ii) whether the studies adhered to national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include productivity costs, we calculated what proportion of total costs were productivity costs. Subsequently, the incremental costs, excluding productivity costs, were calculated and compared with the incremental costs presented in the original article, to analyse the impact of productivity costs on final results. Regression analyses were used to investigate the relationship between the level of productivity costs and the type of depressive disorder, the type of treatment and study characteristics such as time horizon used and productivity cost valuation method.

Results: A total of 81 unique economic evaluations of treatments for adults with depressive disorders were identified, 24 of which included productivity costs in the numerator and one in the denominator. Approximately 69% of the economic evaluations ignored productivity costs. Two-thirds of the studies complied with national guidelines regarding the inclusion of productivity costs. For the studies that included productivity costs, these costs reflected an average of 60% of total costs per treatment arm. The inclusion or exclusion of productivity costs substantially affected incremental costs in a number of studies. Regression analyses showed that the level of productivity costs was significantly associated with study characteristics such as average age, the methods of data collection regarding work time lost, the values attached to lost work time, the type of depressive disorder, the type of treatment provided and the level of direct costs.

Conclusions: Studies that do not include productivity costs may, in many cases, poorly reflect full societal costs (or savings) of an intervention. Furthermore, when comparing total costs reported in studies that include productivity costs, it should be noted that study characteristics such as the methods used to assess productivity costs may affect their level.

Citing Articles

Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire.

Ademiluyi A, van Asselt A, Reneman M Eur J Health Econ. 2025; .

PMID: 39979658 DOI: 10.1007/s10198-025-01756-9.


Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review.

Krol M, Hosseinnia N, Brouwer W, van Roijen L Pharmacoeconomics. 2023; 41(9):1031-1050.

PMID: 37592122 PMC: 10450000. DOI: 10.1007/s40273-023-01304-4.


Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs.

Brouwer W, van Baal P Pharmacoeconomics. 2023; 41(9):1027-1030.

PMID: 37530935 DOI: 10.1007/s40273-023-01307-1.


The association between health costs and physical inactivity; analysis from the Physical Activity at Work study in Thailand.

Akksilp K, Isaranuwatchai W, Teerawattananon Y, Chen C Front Public Health. 2023; 11:1037699.

PMID: 36960361 PMC: 10027789. DOI: 10.3389/fpubh.2023.1037699.


Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects.

Brouwer W, Verbooy K, Hoefman R, van Exel J Pharmacoeconomics. 2023; 41(9):1103-1115.

PMID: 36856941 PMC: 9976676. DOI: 10.1007/s40273-023-01253-y.


References
1.
Meltzer D, Johannesson M . Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making. 1999; 19(4):371-7. DOI: 10.1177/0272989X9901900401. View

2.
Sorensen J, Stage K, Damsbo N, Le Lay A, Hemels M . A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry. 2007; 61(2):100-8. DOI: 10.1080/08039480701226070. View

3.
Simon G, Von Korff M, Ludman E, Katon W, Rutter C, Unutzer J . Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care. 2002; 40(10):941-50. DOI: 10.1097/00005650-200210000-00011. View

4.
Tome M, Isaac M . Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo. Int Clin Psychopharmacol. 1998; 13(4):175-82. DOI: 10.1097/00004850-199807000-00004. View

5.
Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View